qPDL1Nb mRNA-LNP treatment suppresses MC-38 tumour progression. (IMAGE)
Caption
(A) Schematic process of producing in vitro transcribed mRNAs. DNA and RNA helixes drawn via a software developed by Ibuki Kawamata (https://ibuki-kawamata.org). (B–D) The IB analysis shows the levels of mPDL1Nb or qPDL1Nb in the SFM of HEK293 cells transfected with LNP-coated mPDL1Nb mRNA, qPDL1Nb mRNA or Luc mRNA (C), or mPDL1Nb in the serum of mice injected intramuscularly with LNP-coated mPDL1Nb mRNA or Luc mRNA (D). (E–G) MC-38 sCRC tumour growth in C57BL/6 mice (n=7–9) injected intramuscularly with LNP-coated mCTLA-4Nb mRNA, Luc mRNA or mPDL1Nb mRNA. (H) ELISA for the level of mPDL1Nb in the blood of mice injected intramuscularly with LNP-coated mPDL1Nb mRNA. (I) Treatment with LNP-coated qPDL1Nb mRNA via intramuscular injection significantly repressed MC-38 tumour progression in C57BL/6 mice (n=12). (J) ELISA for the level of qPDL1Nb in blood of mice injected intramuscularly with LNP-coated qPDL1Nb mRNA. *p<0.05; two-tailed Student’s t-test; one-way analysis of variance. CTLA-4Nb, cytotoxic T-lymphocyte-associated protein 4 nanobody; HEK293, human embryonic kidney 293 cells; IB, immunoblotting; LNP, lipid nanoparticle; Luc, luciferase; mCTLA-4, murine CTLA-4; mCTLA-4Nb, murine CTLA-4Nb; mPDL1Nb, monomeric PDL1Nb; mRNA, messenger RNA; PDL1Nb, programmed death-ligand 1 nanobody; qPDL1Nb, quadruple PDL1Nb; sCRC, sporadic colorectal cancer; SFM, serum-free medium.
Credit
By Wen-Ming Chu, Li Ma, et al.
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC